Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat1
Authors:
- Jun OuyangJOJun Ouyang
- Xiang WangXWXiang Wang
- Shengyun ZhuSZShengyun Zhu
- Wenlei JiangWJWenlei Jiang
- Shijie QiSQShijie Qi
- Dasheng XuDXDasheng Xu
- Marie J. HebertMHMarie J. Hebert
- Ihor BekerskyIBIhor Bekersky
- William E. FitzsimmonsWFWilliam E. Fitzsimmons
- Huifang ChenHCHuifang Chen
- 15 June 2003
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (11) , 1881-1887
Abstract
The effects of tacrolimus (FK506) and malononitrilamides (MNA) (FK778 and FK779) monotherapy and combination therapy were examined in prevention of acute heart and kidney allograft rejection and reversal of ongoing acute heart allograft rejection in the rat. Brown Norway (RT1n)-to-Lewis (RT11) and ACI (RT1a)-to-Lewis (RT11) combinations were used, respectively, for heart and kidney transplantation models. Immunosuppressants were administered orally from day 1 to day 14 for preventing acute rejection and from day 4 to day 34 after transplantation for the reversal of ongoing acute rejection. In the prevention of acute heart rejection model, recipient rats treated with monotherapy of tacrolimus or MNA (FK778, FK779) showed a dose-related prolongation of mean survival time (MST) compared with naive control rats (P <0.01). The mean survival time in combination therapy of tacrolimus (FK506) and FK778 indicated that an additive to synergistic interaction was produced when compared with the respective monotherapies (combination index [CI]=0.631–1.022). These results were reproducible with tacrolimus and FK779 combination therapy (CI=0.572–0.846). Furthermore, similar results were also found in the prevention of acute kidney allograft rejection in the rat (CI=0.137–0.516). In the reversal of ongoing acute heart allograft rejection, combination therapy of tacrolimus and FK778 demonstrated a strong synergistic interaction (CI=0.166–0.970) compared with monotherapy of tacrolimus or FK778. Combination therapy of tacrolimus and MNA (FK778, FK779) produces synergistic effects in prevention of acute heart and kidney rejection and reversal of ongoing heart allograft rejection in the rat.Keywords
This publication has 26 references indexed in Scilit:
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000
- EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) MONO- AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT SURVIVAL IN THE MONKEY1Transplantation, 2000
- COMPROMISED KIDNEY GRAFT REJECTION RESPONSE IN VERVET MONKEYS AFTER WITHDRAWAL OF IMMUNOSUPPRESSANTS TACROLIMUS AND SIROLIMUS1Transplantation, 2000
- Sirolimus-tacrolimus combination immunosuppressionThe Lancet, 2000
- FK 506 and Rapamycin in Combination Are Not Antagonistic but Produce Extended Small Bowel Graft Survival in the MouseTransplantation Proceedings, 1998
- TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC TRANSPLANTATION IN THE RAT1,2Transplantation, 1997
- Malononitrilamides inhibit T- and B-cell responsiveness in different speciesTransplantation Proceedings, 1997
- A MULTICENTER TRIAL OF FK506 (TACROLIMUS) THERAPY IN REFRACTORY ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1996
- LEFLUNOMIDE IN EXPERIMENTAL TRANSPLANTATIONTransplantation, 1994
- CYCLOSPORINE, FK506, AND RAPAMYCINTransplantation, 1990